Therapeutic implications and pathophysiological role of calprotectin in acute kidney injury

钙卫蛋白在急性肾损伤中的治疗意义和病理生理学作用

• 批准号: 192650496
• 负责人: Professor Dr. Kai Schmidt-Ott
• 金额: --
• 依托单位: Medizinische Klinik I - Allgemeine Innere, Nephrologie, Gastroenterologie, Pneumologie
• 依托单位国家: 德国
• 项目类别: Research Units
• 财政年份: 2011
• 资助国家: 德国
• 起止时间: 2010-12-31 至 2017-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/192650496?language=en
• 关键词: Therapeutic; implications; pathophysiological; role; calprotectin

Acute kidney injury (AKI) is classified according to its origin. There are hemodynamic (prerenal) and non-hemodynamic causes (intrarenal, postrenal). The prognosis of AKI crucially depends on an early diagnosis and immediate onset of therapy. The differential diagnosis of hemodynamic and intrarenal AKI, however, may be difficult. Unfortunately, there is no reliable marker for the non-invasive differentiation of these two entities. The present project investigates the use of urinary calprotectin as a new biomarker for the differentiation of hemodynamic and non-hemodynamic AKI. Calprotectin is a calcium-binding protein that is derived predominantly from neutrophils and monocytes. Being part oft the innate immune system, it is released as a ”damage-associated molecular pattern protein (DAMP)“ in a variety of inflammatory processes. In gastroenterology, fecal calprotectin concentration is a well established marker for the differentiation of inflammatory bowel disease and irritable bowel syndrome. Preliminary results of our group indicate that urinary calprotectin concentrations in patients with hemodynamic AKI is almost identical to healthy controls, whereas urinary calprotectin concentrations are approximately 1000 times higher in intrarenal AKI. If the preliminary results of our pilot study are confirmed by the current project, these findings will be of outstanding clinical relevance: A differentiation between hemodynamic and non-hemodynamic AKI would be available within minutes. “Calprotectin-negative” patients with hemodynamic AKI will immediately receive fluid repletion, whereas “calprotectin-positive” patients with intrarenal failure may require renal biopsy and specific treatment.

急性肾脏损伤（AKI）根据其起源进行分类。有血流动力学（肾上腺动力学）原因（内部，后）。 AKI的预后完全取决于早期诊断和立即开始治疗。然而，血液动力学和肾内AKI的鉴别诊断可能很困难。不幸的是，这两个实体的非侵入性分化没有可靠的标记。本项目调查了将尿钙骨蛋白酶作为分化血液动力学和非骨动力学AKI的新生物标志物的使用。钙染色素是一种钙结合蛋白，主要源自中性粒细胞和单核细胞。作为先天免疫系统的一部分，它在多种炎症过程中以“损伤相关的分子模式蛋白（DAMP）”的形式释放。在胃肠病学中，粪便钙骨蛋白酶浓度是分化炎症性肠病和肠易激综合征的良好标志。我们组的初步结果表明，血液动力学AKI患者的尿钙特染色素浓度几乎与健康对照相同，而尿钙染色素浓度的浓度大约高约1000倍。如果我们的试点研究的初步结果得到当前项目的确认，这些发现将具有出色的临床相关性：在几分钟之内将提供血液动力学和非女性动力学AKI的差异。血液动力学AKI的“钙粘蛋白阴性”患者将立即接受液体置换，而肾上部衰竭的“钙粘蛋白阳性”患者可能需要肾脏活检和特定治疗。

项目成果

Urinary biomarkers for the differentiation of prerenal and intrinsic pediatric acute kidney injury

区分肾前性和内源性小儿急性肾损伤的尿液生物标志物

• DOI: 10.1007/s00467-016-3418-1
• 发表时间: 2016
• 期刊: Pediatric Nephrology
• 影响因子: 3
• 作者: Westhoff JH;Fichtner A;Waldherr S;Pagonas N;Seibert FS;Babel N;Tönshoff B;Bauer F;Westhoff TH
• 通讯作者: Westhoff TH

Dynamics of Urinary Calprotectin after Renal Ischaemia

• DOI: 10.1371/journal.pone.0146395
• 发表时间: 2016-01-08
• 期刊: PLOS ONE
• 影响因子: 3.7
• 作者: Ebbing, Jan;Seibert, Felix S.;Westhoff, Timm H.
• 通讯作者: Westhoff, Timm H.

Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder

• DOI: 10.1007/s00345-013-1227-8
• 发表时间: 2014-12-01
• 期刊: WORLD JOURNAL OF UROLOGY
• 影响因子: 3.4
• 作者: Ebbing, Jan;Mathia, Susanne;Westhoff, Timm H.
• 通讯作者: Westhoff, Timm H.

Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy

• DOI: 10.1159/000494442
• 发表时间: 2018-01-01
• 期刊: KIDNEY & BLOOD PRESSURE RESEARCH
• 影响因子: 2.8
• 作者: Neuhaus, Julia;Bauer, Frederic;Westhoff, Timm H.
• 通讯作者: Westhoff, Timm H.

Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease

• DOI: 10.1159/000492407
• 发表时间: 2018-01-01
• 期刊: KIDNEY & BLOOD PRESSURE RESEARCH
• 影响因子: 2.8
• 作者: Seibert, Felix S.;Sitz, Maximilian;Westhoff, Timm H.
• 通讯作者: Westhoff, Timm H.